8-K: Vivos Therapeutics Reports Full Year 2024 Financial Results, Highlights 26% Product Revenue Increase

Vivos Therapeutics announces its full year 2024 financial results, showcasing a 26% increase in product revenue and a 35% reduction in operating loss.

Summary

• Vivos Therapeutics reported its financial results for the year ended December 31, 2024.
• Revenue increased by approximately $1.2 million, or 9%, to $15.0 million compared to $13.8 million in 2023.
• Product revenue increased 26% year-over-year.
• Gross profit was $9.0 million, compared to $8.3 million in the previous year.
• Gross margin remained consistent at 60%.
• Operating expenses decreased by $5.4 million, or 21%, to $20.2 million due to cost-cutting initiatives.
• The operating loss was reduced by $6.1 million, or 35%, to $11.2 million from $17.3 million in 2023.
• Cash and cash equivalents totaled $6.3 million at the end of 2024, following $17.9 million raised through equity transactions.
• Approximately 58,000 patients have been treated with Vivos' oral appliances worldwide, up from 42,000 at the end of 2023.
• Vivos has trained over 2,000 dentists in the Vivos Method.
• In September 2024, the FDA granted 510(k) clearance for the DNA appliance to treat moderate to severe OSA in children aged 6-17 with malocclusions.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to increased revenue, reduced operating expenses and losses, and FDA clearance, but the company is still operating at a loss.

Positives

• Revenue increased by 9% to $15.0 million.
• Product revenue increased by 26%.
• Operating expenses decreased by 21%.
• Operating loss decreased by 35%.
• The company secured FDA clearance for its DNA appliance to treat OSA in children.
• Vivos raised $17.9 million through equity transactions, strengthening its capital structure.
• The company's new strategic marketing and distribution model is expected to increase top-line revenue with contribution margins of approximately 50% per patient.
• Patient numbers treated with Vivos appliances increased from 42,000 to 58,000.

Negatives

• The increase in revenue was partially offset by decreased revenue from fewer Vivos Integrated Practice (VIP) enrollments.
• The company reported an operating loss of $11.2 million for the year.

Risks

• The company's forward-looking statements are subject to risks, including the ability to implement revenue and marketing strategies.
• There is a risk that some patients may not achieve the desired results from using Vivos products.
• The company faces risks associated with regulatory scrutiny and adverse publicity in the sleep apnea treatment sector.
• Vivos may be unable to secure additional financing on reasonable terms or maintain its Nasdaq listing.

Future Outlook

Vivos believes it is well-positioned to continue improvements in its results throughout 2025 and expects to achieve cash flow positive operations and profitability in the foreseeable future.

Management Comments

• Kirk Huntsman, Vivos Chairman and Chief Executive Officer, stated, 'In 2024, we increased revenue while continuing to lower our cost structure.'
• Mr. Huntsman continued, 'We continued to receive FDA approvals on our products and position ourselves for long-term revenue growth.'
• Mr. Huntsman concluded, 'We believe we have all the necessary tools in place to implement our growth plans, drive increased revenues and achieve cash flow positive operations and profitability in the foreseeable future, and we remain committed to doing so.'

Industry Context

Vivos is focusing on a new marketing and distribution strategy through alliances with sleep healthcare providers, aligning with the trend of integrated healthcare solutions for sleep-related breathing disorders.

Comparison to Industry Standards

• It's difficult to provide a direct comparison without knowing the specific financial details of Vivos' competitors.
• However, companies like Align Technology (ALGN) in the dental device space and ResMed (RMD) in the sleep apnea treatment sector are benchmarks for revenue growth and profitability.
• Vivos' 9% revenue growth is moderate compared to some high-growth medical device companies, but its focus on cost reduction is a positive sign.
• The 60% gross margin is fairly standard for a medical device company.

Stakeholder Impact

• Shareholders may see potential for increased value due to revenue growth and cost reduction.
• Employees may be affected by cost-cutting initiatives, but the company's growth plans could create new opportunities.
• Customers (patients) may benefit from the FDA-cleared DNA appliance and the new strategic marketing and distribution model.
• Suppliers may see increased demand for Vivos products as the company expands its reach.

Next Steps

• Vivos plans to implement its growth plans and drive increased revenues.
• The company aims to achieve cash flow positive operations and profitability.
• Vivos will continue to focus on its new marketing and distribution strategy through alliances with sleep healthcare providers.

Key Dates

Keywords

Vivos Therapeutics, financial results, sleep apnea, OSA, DNA appliance, FDA clearance, revenue, operating loss, equity transactions, oral appliances